Interestingly, HER2/neu protein expressed on breast cancer cells was genetically engineered into anti-DEC205 monoclonal antibody, and in combination with poly I:C and CD40 antibody, elicited robust CD4+ and CD8+ T-cell responses and antibody responses which protected mice against Her2+ breast tumor challenge [179]. Here, ERBB2 is linked to breast cancer.